Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, was elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.
A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.
The Wistar Institute assistant professor Filippo Veglia and team have discovered a key mechanism of how glioblastoma suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses.
A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.
A study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into glioblastoma neuron mimicry and potential therapies to prevent treatment resistance.
The Translational Genomics Research Institute, part of City of Hope, established a fellowship in glioblastoma multiforme research. The Lori Lane/Andrew Spyrow Fellowship honors the lives of Lori Lane and Andrew Spyrow who fought GBM bravely, teaching all of us to experience the joy of life and dedicating their journey to the advancement of treatment improving the quality and longevity of life for those facing this devastating cancer.
A letter to the editor by The Philadelphia Inquirer’s James Neff raises concerns about conflicts of interest in a recent Guest Editorial published in The Cancer Letter. The authors and The Cancer Letter editor respond.
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy.
Letter to the editor by The Philadelphia Inquirer’s James NeffWe see far too many patients with glioblastoma (GBM), an aggressive and almost always fatal malignant brain tumor.
On Sept. 14, FDA approved updated labeling for Temodar (temozolomide) under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date.
